
Insider: Here’s how to treat menstrual migraine
UC headache expert discusses migraine triggers in women
Menstrual migraine isn’t your average headache or migraine. In a 2015 study, women with menstrual migraines reported prolonged migraines and more severe symptoms of nausea than women with non-menstrual migraines.
Insider spoke with Vincent Martin, MD, co-director of the UC Headache and Facial Pain Center and professor of internal medicine, about migraines and menstruation in women. Martin, also a UC Health physician, said that following menopause, “female hormones are falling and this can either drastically improve or sometimes worsen migraine attacks.”
"Birth control pills can worsen headaches in some girls or women because estrogen levels plummet during the placebo week of the birth control pills, which can trigger migraine attacks. One strategy to manage this is to use extended duration birth control pills that only give a placebo week every 3 months instead of monthly," Martin tells Insider.
Specific triggers, notably stress, can also bring on migraines, according to Martin.
Related Stories
Multi-institutional team awarded NCI grant to open novel AML...
June 23, 2025
The University of Cincinnati Cancer Center, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia, funded by a National Cancer Institute grant.
Wrongfully convicted Ohioan awaits $45 million federal lawsuit...
June 22, 2025
The Cincinnati Enquirer speaks with Dean Gillispie, an Ohio Innocence Project exoneree, about compensation from Miami Township following a $45 million federal lawsuit for his wrongful conviction and incarceration.
Novel drug achieves high objective response rate in heavily...
June 18, 2025
Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia.